Cargando…

Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives

Chitosan and its derivatives can alleviate metabolic syndrome by different regulation mechanisms, phosphorylation of AMPK (AMP-activated kinase) and Akt (also known as protein kinase B), suppression of PPAR-γ (peroxisome proliferator-activated receptor-γ) and SREBP-1c (sterol regulatory element–bind...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chen, Zhang, Cuili, Cao, Xuejiao, Feng, Bin, Li, Xinli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764266/
https://www.ncbi.nlm.nih.gov/pubmed/33322383
http://dx.doi.org/10.3390/molecules25245857
_version_ 1783628215889166336
author Yan, Chen
Zhang, Cuili
Cao, Xuejiao
Feng, Bin
Li, Xinli
author_facet Yan, Chen
Zhang, Cuili
Cao, Xuejiao
Feng, Bin
Li, Xinli
author_sort Yan, Chen
collection PubMed
description Chitosan and its derivatives can alleviate metabolic syndrome by different regulation mechanisms, phosphorylation of AMPK (AMP-activated kinase) and Akt (also known as protein kinase B), suppression of PPAR-γ (peroxisome proliferator-activated receptor-γ) and SREBP-1c (sterol regulatory element–binding proteins), and translocation of GLUT4 (glucose transporter-4), and also the downregulation of fatty-acid-transport proteins, fatty-acid-binding proteins, fatty acid synthetase (FAS), acetyl-CoA carboxylase (acetyl coenzyme A carboxylase), and HMG-CoA reductase (hydroxy methylglutaryl coenzyme A reductase). The improved microbial profiles in the gastrointestinal tract were positively correlated with the improved glucose and lipid profiles in hosts with metabolic syndrome. Hence, this review will summarize the current literature illustrating positive correlations between the alleviated conditions in metabolic syndrome hosts and the normalized gut microbiota in hosts with metabolic syndrome after treatment with chitosan and its derivatives, implying that the possibility of chitosan and its derivatives to serve as therapeutic application will be consolidated. Chitosan has been shown to modulate cardiometabolic symptoms (e.g., lipid and glycemic levels, blood pressure) as well as gut microbiota. However, the literature that summarizes the relationship between such metabolic modulation of chitosan and prebiotic-like effects is limited. This review will discuss the connection among their structures, biological properties, and prebiotic effects for the treatment of metabolic syndrome. Our hope is that future researchers will consider the prebiotic effects as significant contributors to the mitigation of metabolic syndrome.
format Online
Article
Text
id pubmed-7764266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77642662020-12-27 Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives Yan, Chen Zhang, Cuili Cao, Xuejiao Feng, Bin Li, Xinli Molecules Review Chitosan and its derivatives can alleviate metabolic syndrome by different regulation mechanisms, phosphorylation of AMPK (AMP-activated kinase) and Akt (also known as protein kinase B), suppression of PPAR-γ (peroxisome proliferator-activated receptor-γ) and SREBP-1c (sterol regulatory element–binding proteins), and translocation of GLUT4 (glucose transporter-4), and also the downregulation of fatty-acid-transport proteins, fatty-acid-binding proteins, fatty acid synthetase (FAS), acetyl-CoA carboxylase (acetyl coenzyme A carboxylase), and HMG-CoA reductase (hydroxy methylglutaryl coenzyme A reductase). The improved microbial profiles in the gastrointestinal tract were positively correlated with the improved glucose and lipid profiles in hosts with metabolic syndrome. Hence, this review will summarize the current literature illustrating positive correlations between the alleviated conditions in metabolic syndrome hosts and the normalized gut microbiota in hosts with metabolic syndrome after treatment with chitosan and its derivatives, implying that the possibility of chitosan and its derivatives to serve as therapeutic application will be consolidated. Chitosan has been shown to modulate cardiometabolic symptoms (e.g., lipid and glycemic levels, blood pressure) as well as gut microbiota. However, the literature that summarizes the relationship between such metabolic modulation of chitosan and prebiotic-like effects is limited. This review will discuss the connection among their structures, biological properties, and prebiotic effects for the treatment of metabolic syndrome. Our hope is that future researchers will consider the prebiotic effects as significant contributors to the mitigation of metabolic syndrome. MDPI 2020-12-11 /pmc/articles/PMC7764266/ /pubmed/33322383 http://dx.doi.org/10.3390/molecules25245857 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yan, Chen
Zhang, Cuili
Cao, Xuejiao
Feng, Bin
Li, Xinli
Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title_full Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title_fullStr Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title_full_unstemmed Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title_short Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives
title_sort intestinal population in host with metabolic syndrome during administration of chitosan and its derivatives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764266/
https://www.ncbi.nlm.nih.gov/pubmed/33322383
http://dx.doi.org/10.3390/molecules25245857
work_keys_str_mv AT yanchen intestinalpopulationinhostwithmetabolicsyndromeduringadministrationofchitosananditsderivatives
AT zhangcuili intestinalpopulationinhostwithmetabolicsyndromeduringadministrationofchitosananditsderivatives
AT caoxuejiao intestinalpopulationinhostwithmetabolicsyndromeduringadministrationofchitosananditsderivatives
AT fengbin intestinalpopulationinhostwithmetabolicsyndromeduringadministrationofchitosananditsderivatives
AT lixinli intestinalpopulationinhostwithmetabolicsyndromeduringadministrationofchitosananditsderivatives